Metraipolis › archive › dc_eef8d17b9769
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41557039
- DOI
- 10.1007/s10549-[numero omesso]-4
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T16:38:20.873Z
- SHA-256 of the archived text
f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b- Stable URL of this page
https://metraipolis.com/documento/dc_eef8d17b9769
How to cite
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039 — Europe PMC (en), https://europepmc.org/article/MED/41557039 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eef8d17b9769 (Metraipolis archive dc_eef8d17b9769, sha256 f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b)
BibTeX
@misc{dceef8d17b9769,
title = {Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41557039},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eef8d17b9769; sha256 f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41557039. Agents can read the archived copy with the MCP tool read_document.